REGN88

Phase 1Biologic

Regeneron

REGN88 is one of 68 biologic programs targeting Rheumatoid Arthritis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rheumatoid ArthritisActive, not recruiting

AsthmaActive, not recruiting

Rheumatoid ArthritisPhase 1

Active, not recruiting

AsthmaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Veramyst

GSK

Preclinical

46 2

Xolair

Roche

Preclinical

25 3

Singulair

AstraZeneca

Preclinical

17 4

Nucala

GGlaxo Dba Glaxosmithkline

Preclinical

35 5

Cinqair

Teva

Preclinical

13 6

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

30 7

Asmanex

Novartis

Preclinical

5 8

Celexa

AbbVie

Preclinical

1 9

Spiriva

Boehringer Ingelheim

Preclinical

8 10

Qvar

Chiesi Farmaceutici S.p.A.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Rheumatoid Arthritis3 trials

A Multiple-dose Study of the Safety and Tolerability of REGN88(SAR153191) in Rheumatoid Arthritis Subjects

Completed· Regeneron logo

Regeneron·Phase 1·NCT01011959·60 enrolled

A Safety and Tolerability Study of REGN88(SAR153191) in Subjects With Rheumatoid Arthritis

Completed· Regeneron logo

Regeneron·Phase 1·NCT01026519·32 enrolled

Safety Study of a Single Dose of REGN88(SAR153191)in Patients With Rheumatoid Arthritis

Completed· Regeneron logo

Regeneron·Phase 1·NCT01055899·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for REGN88. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — REGN88 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for REGN88. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Regeneron company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: Regeneron

REGN88

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Rheumatoid Arthritis3 trials

References

Drug Info

Quick Facts

Related News